论文部分内容阅读
目的:评估乳腺癌前哨淋巴结活检(SenitallymphnodebiopsySLNB)对预测腋窝淋巴结转移状态的价值及其临床意义。方法:临床Ⅰ、Ⅱ期原发女性乳腺癌41例,体检无腋淋巴结肿大或虽有肿大而估计非转移性。术中在原发肿瘤周围注射亚甲蓝示踪定位,行SLNB和腋淋巴结清扫(AxillarylymphnodedissectionALND)。术后对全部前哨淋巴结(SLN)和腋淋巴结(ALN)行常规病理检查。结果:41例中检出SLN者32例,检出率为78.0%。其中N0组25例准确度为96.0%;阳性预测符合率100%;假阴性0例,阴性预测符合率100%。N1组7例准确度仅57.1%,假阴性2例,阴性预测符合率0。结论:应用亚甲蓝示踪定位SLNB,能准确预测(T1、T2)N0M0乳腺癌患者的转移状态,宜于推广应用。
Objective: To evaluate the value of SenitallymphnodebiopsySLNB in predicting axillary lymph node metastasis and its clinical significance. Methods: The clinical stage Ⅰ, Ⅱ primary breast cancer in 41 cases, no axillary lymph node enlargement or undetectable physical examination. Intraoperative injection of methylene blue tracer around the primary tumor location, line SLNB and axillary lymph node dissection (AxillarylymphnodedisctionALND). All sentinel lymph nodes (SLNs) and axillary lymph nodes (ALNs) underwent routine pathological examination. Results: 32 cases of SLN were detected in 41 cases, the detection rate was 78.0%. Among them, the accuracy of N0 group was 96.0% in 25 cases, the coincidence rate of positive predictive value was 100%, the false negative percentage was 0 case and the negative predictive value was 100%. In N1 group, the accuracy was only 57.1% in 7 cases, false negative in 2 cases and negative predictive agreement in 0. Conclusion: The localization of SLNB using methylene blue tracing can accurately predict the metastatic status of patients with (T1, T2) N0M0 breast cancer and should be widely applied.